Stock listing
NASDAQ:RNTX Rein Therapeutics, Inc. Stock
Home listing (NASDAQ) of Rein Therapeutics, Inc.
Follow Rein Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:RNTX
$0.337 USD -0.018 (-5.2%)
Close on Nov 20, 2026
- Day range
- $0.335 – $0.390 USDNov 20, 2026
- Volume
- 668,573 sharesNov 20, 2026
- Market cap
- $29.06M USDAt the close on Nov 20, 2026 · price × 86.27M shares outstanding
- 52-week range
- $0.284 – $2.100 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $371,699 USDMedian day 348,766 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RNTX · Home | $0.337 USD | -0.018 (-5.2%) | 668,573 | $0.358 | $0.390 | $0.335 | $0.355 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RNTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.337 | -0.018 | -5.2% | $0.358 | $0.390 | $0.335 | 668,573 | |
| $0.355 | -0.001 | -0.3% | $0.366 | $0.390 | $0.350 | 815,803 | |
| $0.356 | -0.044 | -10.9% | $0.380 | $0.405 | $0.325 | 2,483,079 | |
| $0.400 | -0.152 | -27.5% | $0.500 | $0.500 | $0.284 | 8,481,447 | |
| $0.552 | -0.008 | -1.4% | $0.551 | $0.574 | $0.501 | 488,672 | |
| $0.560 | -0.046 | -7.6% | $0.600 | $0.605 | $0.552 | 348,766 | |
| $0.606 | +0.016 | +2.7% | $0.602 | $0.626 | $0.591 | 307,100 | |
| $0.590 | -0.031 | -5.0% | $0.630 | $0.630 | $0.558 | 528,000 | |
| $0.621 | +0.007 | +1.1% | $0.624 | $0.650 | $0.586 | 319,900 | |
| $0.614 | +0.002 | +0.3% | $0.594 | $0.630 | $0.575 | 408,700 | |
| $0.612 | -0.047 | -7.1% | $0.650 | $0.655 | $0.572 | 303,700 | |
| $0.659 | -0.009 | -1.3% | $0.688 | $0.728 | $0.654 | 213,900 | |
| $0.668 | +0.033 | +5.2% | $0.668 | $0.705 | $0.634 | 256,400 | |
| $0.635 | -0.035 | -5.2% | $0.690 | $0.711 | $0.620 | 392,700 | |
| $0.670 | -0.057 | -7.8% | $0.700 | $0.700 | $0.660 | 121,500 | |
| $0.727 | +0.012 | +1.7% | $0.707 | $0.750 | $0.677 | 189,000 | |
| $0.715 | +0.011 | +1.6% | $0.697 | $0.741 | $0.660 | 389,700 | |
| $0.704 | +0.121 | +20.8% | $0.600 | $0.720 | $0.590 | 622,100 | |
| $0.583 | +0.001 | +0.2% | $0.570 | $0.609 | $0.560 | 394,100 | |
| $0.582 | -0.020 | -3.3% | $0.595 | $0.612 | $0.572 | 331,300 | |
| $0.602 | -0.023 | -3.7% | $0.620 | $0.624 | $0.590 | 305,200 | |
| $0.625 | +0.030 | +5.0% | $0.607 | $0.650 | $0.595 | 266,100 | |
| $0.595 | +0.043 | +7.8% | $0.545 | $0.607 | $0.543 | 296,400 | |
| $0.552 | -0.038 | -6.4% | $0.580 | $0.615 | $0.552 | 502,200 | |
| $0.590 | -0.038 | -6.1% | $0.613 | $0.622 | $0.570 | 372,000 | |
| $0.628 | +0.042 | +7.2% | $0.600 | $0.666 | $0.551 | 1,372,900 | |
| $0.586 | -0.169 | -22.4% | $0.755 | $0.755 | $0.540 | 1,143,400 | |
| $0.755 | -0.030 | -3.8% | $0.777 | $0.777 | $0.750 | 142,500 | |
| $0.785 | -0.009 | -1.1% | $0.770 | $0.788 | $0.750 | 108,100 | |
| $0.794 | +0.025 | +3.3% | $0.761 | $0.810 | $0.761 | 307,500 | |
| $0.769 | -0.020 | -2.5% | $0.784 | $0.784 | $0.746 | 477,600 | |
| $0.789 | -0.036 | -4.4% | $0.800 | $0.817 | $0.780 | 447,000 | |
| $0.825 | 0.000 | 0.0% | $0.825 | $0.834 | $0.809 | 185,600 | |
| $0.825 | +0.024 | +3.0% | $0.815 | $0.870 | $0.810 | 336,100 | |
| $0.801 | -0.051 | -6.0% | $0.850 | $0.863 | $0.780 | 480,500 | |
| $0.852 | +0.048 | +6.0% | $0.804 | $0.899 | $0.759 | 1,108,000 | |
| $0.804 | +0.014 | +1.8% | $0.800 | $0.826 | $0.762 | 419,000 | |
| $0.790 | +0.069 | +9.6% | $0.720 | $0.810 | $0.720 | 388,400 | |
| $0.721 | -0.027 | -3.6% | $0.763 | $0.790 | $0.720 | 162,800 | |
| $0.748 | +0.004 | +0.5% | $0.741 | $0.820 | $0.730 | 112,800 | |
| $0.744 | -0.026 | -3.4% | $0.770 | $0.785 | $0.715 | 296,300 | |
| $0.770 | -0.025 | -3.1% | $0.790 | $0.817 | $0.770 | 441,400 | |
| $0.795 | 0.000 | 0.0% | $0.807 | $0.821 | $0.790 | 87,100 | |
| $0.795 | -0.005 | -0.6% | $0.811 | $0.815 | $0.790 | 178,200 | |
| $0.800 | +0.011 | +1.4% | $0.792 | $0.820 | $0.780 | 492,500 | |
| $0.789 | +0.087 | +12.4% | $0.715 | $0.790 | $0.703 | 262,700 | |
| $0.702 | -0.006 | -0.8% | $0.710 | $0.740 | $0.700 | 266,400 | |
| $0.708 | -0.083 | -10.5% | $0.784 | $0.790 | $0.700 | 556,100 | |
| $0.791 | +0.006 | +0.8% | $0.801 | $0.845 | $0.750 | 346,800 | |
| $0.785 | +0.004 | +0.5% | $0.799 | $0.813 | $0.770 | 295,600 | |
| $0.781 | -0.047 | -5.7% | $0.820 | $0.835 | $0.772 | 240,800 | |
| $0.828 | -0.035 | -4.1% | $0.880 | $0.880 | $0.822 | 265,300 | |
| $0.863 | -0.026 | -2.9% | $0.930 | $0.960 | $0.850 | 760,300 | |
| $0.889 | +0.045 | +5.3% | $0.920 | $0.920 | $0.850 | 984,800 | |
| $0.844 | +0.069 | +8.9% | $0.790 | $0.870 | $0.790 | 568,000 | |
| $0.775 | +0.022 | +2.9% | $0.760 | $0.791 | $0.736 | 489,100 | |
| $0.753 | +0.003 | +0.4% | $0.749 | $0.765 | $0.729 | 344,300 | |
| $0.750 | -0.012 | -1.6% | $0.770 | $0.776 | $0.741 | 546,100 | |
| $0.762 | -0.021 | -2.7% | $0.788 | $0.788 | $0.762 | 259,000 | |
| $0.783 | -0.017 | -2.1% | $0.792 | $0.811 | $0.783 | 136,500 | |
| $0.800 | 0.000 | 0.0% | $0.810 | $0.824 | $0.780 | 324,700 | |
| $0.800 | 0.000 | 0.0% | $0.804 | $0.822 | $0.771 | 276,754 | |
| $0.800 | -0.018 | -2.2% | $0.820 | $0.824 | $0.770 | 463,562 | |
| $0.818 | +0.024 | +3.0% | $0.800 | $0.855 | $0.771 | 580,000 | |
| $0.794 | +0.002 | +0.3% | $0.856 | $0.877 | $0.775 | 2,489,200 |
Splits
1 split · NASDAQ:RNTX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:RNTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results
Latest deck · September 2026
Technical Presentation (September 2026)
Technical · 55 slides
Latest news
Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results
Nov 16, 2026
Closed $0.40 (-27.5%) on Nov 16, 2026
Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 2, 2026
Closed $0.635 (-5.2%) on Nov 2, 2026
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Sep 4, 2026
Closed $0.889 (+5.3%) on Sep 4, 2026
Rein Therapeutics to Present at Upcoming September Investor Conferences
Sep 3, 2026
Closed $0.889 (+5.3%) on Sep 4, 2026
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Aug 20, 2026
Closed $0.794 (+0.3%) on Aug 20, 2026
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 14, 2026
Closed $0.806 (+2.3%) on Aug 14, 2026
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Aug 4, 2026
Closed $0.764 (+2.4%) on Aug 4, 2026
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
Jul 21, 2026
Closed $0.895 (+6.0%) on Jul 21, 2026
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Jun 11, 2026
Closed $0.926 (+0.7%) on Jun 11, 2026
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
May 18, 2026
Closed $1.04 (-1.0%) on May 18, 2026
Rein Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 106 in all · newest Nov 16, 2026 · oldest 2020
- Decks
- 4 decks · latest September 2026
Where Rein Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RNTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RNTX | BOATS | United States | USD |
| Tradegate:015A | Tradegate | Germany | EUR |
Valuation
Price/book 0.6× against a median of 4.5×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$6.43M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.11
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Rein Therapeutics, Inc. · NASDAQ:RNTX | US$29.06M | −US$6.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 2.11 |
| Pacific Software, Inc. · OTC:PFSF | US$29.86M | US$38.10M | n/a | n/a | n/a | n/a | n/a | n/a | 1.57 |
| NextCure, Inc. · NASDAQ:NXTC | US$29.53M | US$20.81M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.85 |
| NurExone Biologic Inc · TSXV:NRX | US$29.53M | US$28.52M | n/a | n/a | n/a | 23.3× | n/a | 0.0× | 0.00 |
| BioHarvest Sciences, Inc. · NASDAQ:BHST | US$29.47M | US$34.54M | n/a | 1.0× | n/a | 1.8× | −34.7% | 1.0× | 0.43 |
| Thiogenesis Therapeutics Corp · TSXV:TTI | US$29.28M | US$24.21M | n/a | n/a | n/a | 6.2× | n/a | 0.0× | 0.37 |
| NanoViricides, Inc. · AMEX:NNVC | US$29.11M | US$26.54M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.82 |
| Nicox SA · EURONEXT:ALCOX | US$29.05M | US$25.67M | n/a | 1.4× | n/a | 3.8× | −14.4% | 0.4× | n/a |
| Serina Therapeutics, Inc. · AMEX:SER | US$28.45M | US$12.42M | n/a | 99.3× | n/a | 2.0× | n/a | 0.2× | 1.60 |
| ProMIS Neurosciences Inc. · NASDAQ:PMN | US$28.43M | −US$15.68M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.83 |
| Entropy Neurodynamics Limited · ASX:ENP | US$28.12M | US$24.43M | n/a | n/a | n/a | 5.8× | n/a | 0.0× | n/a |
| Median of the others | US$29.20M | US$25.05M | 1.4× | 4.5× | −24.5% | 0.0× | 1.20 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 6.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.46 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Brian Windsor | President and CEO |
| Ron Chen | VP, Finance and Corporate Controller |
| Tim Cunningham | Interim Chief Financial Officer |
| Kristie Lauterbach | VP, Quality Assurance |
| Matt Karpen | VP, CMC |
| Cory Hogaboam | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Brian Windsor | President and CEO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · Before open | −27.6% |
| Q2 2026 | Aug 14, 2026 · Before open | +2.3% |
| Q1 2026 | May 15, 2026 · Before open | −7.1% |
| Q3 2025 | Nov 14, 2025 · Before open | −7.4% |
| Q2 2025 | Aug 14, 2025 · After close | +3.4% |
| Q1 2025 | May 15, 2025 · After close | −6.4% |
| Q3 2024 | Nov 14, 2024 · After close | −13.3% |
| Q2 2024 | Aug 14, 2024 · After close | −10.8% |
| Q1 2024 | May 15, 2024 · After close | −1.3% |
| Q3 2023 | Oct 13, 2023 · After close | +5.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 8, 2023 | 0.0% |
| Q1 2023 | May 8, 2023 · Before open | +8.6% |
| Q4 2022 | Mar 20, 2023 | +2.9% |
| Q3 2022 | Nov 1, 2022 · Before open | +2.5% |
| Q2 2022 | Aug 15, 2022 · After close | +2.8% |
| Q1 2022 | May 5, 2022 · After close | −0.7% |
| Q4 2021 | Mar 28, 2022 | −11.8% |
| Quarter to Sep 30, 2021 | Nov 12, 2021 · Before open | −6.2% |
| Quarter to Jun 30, 2021 | Aug 11, 2021 · After close | +8.0% |
| Quarter to Mar 31, 2021 | May 11, 2021 · After close | +3.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2026) | Technical | 55 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 32 slides | August 2026 |
| Aileron Therapeutics — Merger or Acquisition (October 2023) | Merger or acquisition | 40 slides | Oct 31, 2023 |
| Aileron Therapeutics — Corporate Update (June 2020) | Corporate update | 6 slides | Jun 1, 2020 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$50M · US$1 a share · Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC Dealers: Konik Capital Partners, LLC, a division of T.R. Winston & Company, LLC (lead) Use of proceeds: Fully fund the Phase 2 trial of LTI-03 in IPF through completion, plus working capital and general corporate purposes | Apr 30, 2026 |
| Pre-paid advances repayable in common stock Announced: up to US$6M Buyers: Yorkville Advisors Global, LP (affiliate) (up to $6 million in pre-paid advances, initial $1 million funded at signing) Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes | Jul 30, 2025 |
| Common stock under standby equity purchase agreement Announced: up to US$15M Buyers: Yorkville Advisors Global, LP (affiliate) (up to $15 million of common stock over 36 months at Rein's option) Use of proceeds: RENEW Phase 2 trial of LTI-03 for IPF, research and development of other product candidates, working capital and general corporate purposes | Jul 30, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as AILERON THERAPEUTICS INC. Priced at US$15.00 a share on Jun 28, 2017.
- Price
- US$15.00 a share
- Shares offered
- 3,750,000 shares of common stock
- Offering size
- US$56.3 million
- Underwriters' option
- Up to 562,500 more shares
- Underwriters
- BofA Merrill Lynch, Jefferies, William Blair, Canaccord Genuity · In the order on the cover
- Shares delivered
- On or about Jul 5, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 10, 2015 |
| Filed publicly | Jun 2, 2017 |
| Amended once | Jun 19, 2017 |
| Shares registered with an exchange | Jun 23, 2017 |
| Declared effective by the SEC | Jun 28, 2017 |
| Final prospectus, with the price | Jun 29, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 29, 2017 |
| EFFECT · Notice that a registration is effective | Jun 28, 2017 |
| CORRESP · Letter to the SEC | Jun 26, 2017 |
| CORRESP · Letter to the SEC | Jun 26, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Jun 23, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 23, 2017 |
| CORRESP · Letter to the SEC | Jun 19, 2017 |
| S-1/A · Registration statement, amended | Jun 19, 2017 |
| CORRESP · Letter to the SEC | Jun 7, 2017 |
| S-1 · Registration statement | Jun 2, 2017 |
All 19 filings
| Filing | Filed |
|---|---|
| DRSLTR · Letter to the SEC with a draft | May 26, 2017 |
| DRS/A · Draft registration statement, amended | May 26, 2017 |
| UPLOAD · Letter from the SEC | May 12, 2017 |
| DRS/A · Draft registration statement, amended | Apr 17, 2017 |
| DRS/A · Draft registration statement, amended | Mar 28, 2016 |
| DRS/A · Draft registration statement, amended | Dec 29, 2015 |
| DRSLTR · Letter to the SEC with a draft | Dec 29, 2015 |
| UPLOAD · Letter from the SEC | Oct 5, 2015 |
| DRS · Draft registration statement | Sep 10, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 29, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1.00K | 63.0K | ||||||||
| Gross profit | -1.00K | -63.0K | ||||||||
| Research and development | 11.0M | 14.2M | 3.99M | 18.0M | 17.0M | 11.2M | 17.7M | 18.4M | 14.2M | 10.3M |
| Selling, general and administrative | 10.9M | 13.9M | 11.4K | 9.68K | 9.60K | 9.33K | ||||
| Operating income | -50.6M | -65.1M | -16.3M | -27.6M | -26.6M | -20.5M | -30.0M | -31.9M | -23.0M | -18.2M |
| Depreciation and amortization | 1.00K | 63.0K | 119.0K | 169.0K | 121.0K | 163.0K | 155.0K | 218.0K | 129.0K | 232.0K |
| EBITDA | -50.6M | -65.0M | -16.2M | -27.5M | -26.5M | -20.3M | -29.8M | -31.7M | -22.9M | -17.9M |
| Income before tax | -50.6M | -64.3M | -15.7K | -27.3K | -26.2K | -21.2K | ||||
| Income tax | -712.0K | -1.54M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -49.9M | -62.9M | -15.7M | -27.3M | -26.2M | -27.3M | -29.4M | -31.5M | -22.6M | -18.1M |
| Earnings per share, basic | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | -0.61 | -1.20 | -2.14 | -3.04 | -42.35 |
| Earnings per share, diluted | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 | -0.61 | -1.20 | -2.14 | -3.04 | -42.35 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.21M | 12.9M | 17.3M | 5.19M | 3.60M | 7.05M | 5.31M | 10.6M | 11.9M | 20.7M |
| Short-term investments | 0 | 0 | 16.0M | 42.3M | 6.76M | 13.0M | 10.1M | 38.9M | 0 | |
| Current assets | 4.33M | 13.7M | 18.3M | 21.9M | 48.2M | 16.3M | 19.6M | 21.8M | 51.8M | 21.1M |
| Property, plant and equipment | 0 | 1.00K | 19.0K | 70.0K | 128.0K | 15.0K | 295.0K | 7.29M | 154.0K | 107.0K |
| Goodwill | 6.33M | 6.33M | 6.33M | 0 | ||||||
| Total assets | 24.2M | 62.2M | 106.0M | 22.0M | 48.5M | 16.3M | 26.5M | 30.3M | 52.7M | 22.0M |
| Accounts payable | 3.98M | 911.0K | 1.19M | 1.72M | 1.21M | 1.60M | 1.45M | 1.73M | 1.60M | 1.97M |
| Current liabilities | 6.18M | 5.75M | 4.38M | 3.38M | 4.51M | 3.96M | 5.84M | 5.37M | 4.89M | 4.07M |
| Long-term debt | 219.0K | |||||||||
| Total debt | 48.0K | 33.0K | 162.0K | 387.0K | 5.03M | 5.34M | ||||
| Total liabilities | 7.24M | 7.80M | 7.71M | 3.38M | 4.58M | 4.18M | 10.4M | 10.7M | 4.89M | 4.08M |
| Shareholders' equity | 16.9M | 54.4M | 98.3M | 18.6M | 43.9M | 12.2M | 16.0M | 19.6M | 47.8M | -111.8M |
| Shares outstanding | 27.6M | 21.7M | 4.89M | 4.54M | 4.53M | 43.8M | 27.8M | 14.7M | 14.7M | 432.4K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -19.4M | -22.3M | -19.8M | -24.9M | -23.8M | -20.5M | -26.5M | -27.9M | -20.5M | -15.0M |
| Capital spending | 0 | 0 | 0 | 0 | -157.0K | -5.00K | -151.0K | -4.42M | -142.0K | 0 |
| Free cash flow | -19.4M | -22.3M | -19.8M | -24.9M | -23.9M | -20.5M | -26.6M | -32.3M | -20.7M | -15.0M |
| Cash from investing | 0 | 16.2M | 26.5M | -35.9M | 6.41M | -2.81M | 24.7M | -38.9M | -25.0K | |
| Cash from financing | 9.76M | 17.8M | 15.8M | 0 | 55.7M | 15.8M | 24.0M | 2.52M | 50.6M | 32.0M |
| Change in cash | -9.65M | -4.47M | 12.1M | 1.59M | -4.01M | 1.74M | -5.32M | -723.0K | -8.85M | 16.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 8-K · Current report | Sep 4, 2026 | Current report | SEC |
| 8-K · Current report | Aug 27, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 21, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| ARS · Annual report to shareholders | Jun 8, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 8, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 8, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | May 28, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 4, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 4, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 28, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 28, 2026 | Other filings | SEC |
| S-1 · Registration statement | Apr 28, 2026 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 27, 2026 | Annual report | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 19, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 16, 2026 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Dec 31, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Dec 29, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 28, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 24, 2025 | Material contract | SEC |
| 8-K · Current report | Oct 9, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 26, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 22, 2025 | Current report | SEC |
| 8-K · Current report | Sep 9, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Sep 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 4, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 4, 2025 | Other filings | SEC |
| S-1 · Registration statement | Sep 3, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 19, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 30, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jul 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 23, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jul 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jul 11, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Jun 24, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 24, 2025 | Current report | SEC |
| 8-K · Current report | Jun 12, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 23, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 21, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 16, 2025 | Offer document | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 424B5 · Prospectus | May 15, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | May 12, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 12, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 12, 2025 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 22, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 17, 2025 | Current report | SEC |
| 10-K · Annual report | Apr 7, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Jan 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 21, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 26, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jul 26, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Jul 26, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Jul 9, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 9, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 9, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | May 16, 2024 | Insider trade | SEC |
| 8-K · Current report | May 16, 2024 | Management or board change | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 4/A · Change in ownership, amended | May 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 8-K · Current report | May 1, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 1, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 1, 2024 | Offer document | SEC |
| FWP · Free writing prospectus | May 1, 2024 | Offer document | SEC |
| 8-K · Current report | May 1, 2024 | Results | SEC |
| 3 · Initial statement of ownership | Apr 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 29, 2024 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 16, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Apr 15, 2024 | Results | SEC |
| 10-K · Annual report | Apr 15, 2024 | Annual report | SEC |
| 4/A · Change in ownership, amended | Apr 10, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Apr 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 2, 2024 | Insider trade | SEC |
| NT 10-K · Late filing notice | Apr 1, 2024 | Explanation request | SEC |
| 8-K · Current report | Mar 29, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 15, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 6, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Mar 5, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Mar 1, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 29, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2024 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Feb 6, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 5, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Feb 1, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 1, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Jan 31, 2024 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Jan 29, 2024 | Offer document | SEC |
| S-3 · Registration statement | Jan 29, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Jan 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jan 29, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jan 29, 2024 | Current report | SEC |
| 8-K · Current report | Jan 25, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jan 19, 2024 | Meeting notice | SEC |
| 8-K/A · Current report, amended | Jan 11, 2024 | Current report | SEC |
| 8-K · Current report | Jan 10, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| D | Nov 16, 2023 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 13, 2023 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 3, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 31, 2023 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Oct 13, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 11, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | May 8, 2023 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2023 | Annual report | SEC |
| 10-K · Annual report | Mar 20, 2023 | Annual report | SEC |
| 8-K · Current report | Feb 23, 2023 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 10, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Nov 1, 2022 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jul 8, 2022 | Management or board change | SEC |
| 8-K · Current report | Jun 29, 2022 | Current report | SEC |
| 424B5 · Prospectus | Jun 21, 2022 | Offer document | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 17, 2022 | Other filings | SEC |
| 8-K · Current report | Jun 16, 2022 | Management or board change | SEC |
| CORRESP · Letter to the SEC | Jun 14, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 14, 2022 | Other filings | SEC |
| DEL AM | Jun 13, 2022 | Other filings | SEC |
| 8-K · Current report | Jun 8, 2022 | Current report | SEC |
| S-3 · Registration statement | Jun 7, 2022 | Offer document | SEC |
| 8-K · Current report | Jun 7, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | May 5, 2022 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2022 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2022 | Meeting notice | SEC |
This page holds 200 of 527 filings. Open Filings
Cap table
Built by 6ix from Rein Therapeutics, Inc.’s releases · as of Nov 12, 2026
- Common shares
- 86,267,032
- Fully diluted
- 86,267,032
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 86,267,032 | Nov 12, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 86,267,032 |
| Sep 30, 2026 | 86,267,032 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| William C. Fairey Other companies: Ascendis Pharma A/S (Director · Since at least Mar 18, 2026); KalVista Pharmaceuticals, Inc. (Director · Since at least Apr 18, 2024); Mirum Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2021); MyoKardia Inc (EVP, Chief Commercial Officer · Jan 28, 2019 – Nov 17, 2020 · Past); ChemoCentryx Inc. (Chief Operating Officer · Jan 3, 2018 – Jan 3, 2018 · Past) | Director · Since at least Oct 31, 2023 |
| Muneer A Satter Other companies: Annexon, Inc. (Director · Since at least Jul 23, 2020); Whitehawk Therapeutics, Inc. (Director · Mar 15, 2017 – Jun 18, 2019 · Past); Immunic, Inc. (Director · Apr 16, 2014 – Sep 13, 2018 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past) | See Remarks, Director · Jun 8, 2020 – Jan 8, 2021 · Past |
| Timothy M Cunningham Other companies: Neuphoria Therapeutics Inc. (Chief Financial Officer · Jul 1, 2024 – Jul 1, 2024 · Past); Alaunos Therapeutics, Inc. (interim CFO · Feb 17, 2021 – Feb 17, 2021 · Past); Organogenesis Holdings Inc. (Chief Financial Officer · Dec 10, 2018 – Apr 22, 2020 · Past) | See Remarks · May 16, 2024 – May 16, 2024 · Past |
| Brian M Gallagher Jr Other companies: eFFECTOR Therapeutics Inc (Director · Aug 25, 2021 – Jun 13, 2024 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Jul 2, 2018 · Past) | Director · Jun 28, 2017 – Jul 25, 2017 · Past |
| James Brian Windsor Other companies: TFF Pharmaceuticals Inc (Chief Science Officer, Director · Oct 24, 2019 – Dec 7, 2020 · Past) | See Remarks, Director · Since at least Oct 31, 2023 |
| Kathryn Gregory Other companies: Longevity Health Holdings, Inc. (Director · Jul 14, 2023 – Oct 11, 2024 · Past) | SVP, Chief Business Officer · Feb 25, 2019 – Jan 31, 2020 · Past |
| Rick Wanstall Other companies: Oncorus Inc (CFO and Treasurer · May 10, 2022 – May 25, 2022 · Past) | See Remarks · Mar 27, 2019 – Mar 30, 2022 · Past |
| Tim Cunningham Other companies: Neuphoria Therapeutics Inc. (Fractional CFO · Since at least Nov 4, 2026) | Interim Chief Financial Officer · Since at least Nov 4, 2026 |
| Brian Windsor | President and CEO · Since at least Nov 2, 2026 |
| Caleb Maxfield Winder | Director · Jun 28, 2017 – Jun 21, 2018 · Past |
All 18 people
| Person | Seat |
|---|---|
| Cory Hogaboam | Chief Scientific Officer · Since at least Aug 4, 2026 |
| Kira Nelson | See Remarks · Jun 28, 2017 – Jul 25, 2017 · Past |
| Kristie Lauterbach | VP, Quality Assurance · Since at least Nov 5, 2026 |
| Matt Karpen | VP, CMC · Since at least Nov 4, 2026 |
| Nolan Howard Sigal | Director · Apr 2, 2019 – Jun 15, 2022 · Past |
| Reinhard J Ambros | Director · Since at least Jun 28, 2017 |
| Ron Chen | VP, Finance and Corporate Controller · Since at least Nov 4, 2026 |
| Scott Kapnick | Director · Aug 14, 2018 – Aug 14, 2018 · Past |
Log in to ask 6ix AI your own questions about Rein Therapeutics, Inc.